Graft loss censored for death · patients with kidney transplant recipients
Mycophenolate mofetil (MMF) leads to lower graft loss, censored for death compared with azathioprine (AZA) (high certainty).
1 finding from 1 review
Malignancy · patients with kidney transplant recipients
It is very uncertain whether mycophenolate mofetil (MMF) changes malignancy, any compared with azathioprine (AZA) (very low certainty).
1 finding from 1 review
Acute rejection, steroid resistant/antibody treated As reported in the articles · patients with kidney transplant recipients
Mycophenolate mofetil (MMF) leads to lower acute rejection, steroid resistant/antibody treated As reported in… compared with azathioprine (AZA) (high certainty).
1 finding from 1 review
Infection, CMV tissue invasive As reported in the articles · patients with kidney transplant recipients
Mycophenolate mofetil (MMF) leads to higher infection, CMV tissue invasive As reported in the articles compared with azathioprine (AZA) (high certainty).
1 finding from 1 review
Acute rejection, total Any treated acute rejection, including biopsy‐proven · patients with kidney transplant recipients
Mycophenolate mofetil (MMF) leads to lower acute rejection, total Any treated acute rejection, including… compared with azathioprine (AZA) (high certainty).
1 finding from 1 review
Chronic allograft nephropathy Biopsy required in 2 RCTs, one study with optional biopsy · patients with kidney transplant recipients
Mycophenolate mofetil (MMF) may leads to lower chronic allograft nephropathy Biopsy required in 2 RCTs, one study… compared with azathioprine (AZA) (low certainty).
1 finding from 1 review